High-throughput oncogene mutation detection in human cancers by mass spectrometry-based genotyping
Researchers have devised a new method to detect a spectrum of known gene mutations in a variety of cancer genes that they say is both sensitive and cost-effective. They say that if validated, this method of genotyping might ultimately be used in "real time" to match patients to available targeted therapies. Results were presented at the first meeting on Molecular Diagnostics in Cancer Ther...Scientists tie several cancers to common 'oncogene engine'
Researchers at Dana-Farber Cancer Institute report that a common "oncogene engine" ?a small family of malfunctioning cell growth switches ?drives several seemingly unrelated, lethal forms of cancer, including malignant melanoma. The finding suggests that it may be possible to attack these different cancers with the same therapy. Reporting in the June issue of Cancer Cell, the scientists sh...Pair of microRNA molecules controls major oncogene in most common leukemia
Researchers at Ohio State University have discovered that two microRNA (miRNA) molecules help control the oncogene responsible for a dangerous form of B-cell chronic lymphocytic leukemia (B-CLL), the most common human leukemia in the world. Their findings, published in the December 15 issue of Cancer Research, demonstrate that miRNAs are emerging as powerful regulators of gene expression...The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
Drs. Frank Slack, Steven Johnson, and Helge Grosshans, and Ms. Kristy Reinert at Yale University, in collaboration with Ambion scientists, discovered that the microRNA (miRNA) family regulates the expression of C. elegans...Pair of MicroRNA Molecules Controls Major Oncogene in Most Common Leukemia
Researchers at Ohio State University have discovered that two microRNA (miRNA) molecules help control the oncogene responsible for a dangerous form of B-cell chronic// lymphocytic leukemia (B-CLL), the most common human leukemia in the world. Their findings, published in the December 15 issue of Cancer Research, demonstrate that miRNAs are emerging as powerful regulators of gene exp...OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO
VANCOUVER and CARLSBAD, CA, May 31, 2007 /PRNewswire-FirstCall/- OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. todayannounced that preliminary data from ongoing clinical studies ofOGX-011 will be presented at the American Society of ClinicalOncology Annual Meeting (ASCO). Presentations will include datafrom a Phase II clinical study of OGX-011 in hormone refractoryprostate c...